Arthrosi's gout drug financed with $75 million Series D

The U.S. company Arthrosi Therapeutics has bagged $75 million in a Series D round to fund the clinical development of a small molecule drug for chronic gout.

Related Keywords

China ,Litain Yeh ,Ruiao Biopharmaceutical Technology ,Reichstein Biotech Hk Co ,Guangrun Health Industry ,Apichope Pharmaceuticals ,Reichstein Biotech ,Investigational New Drug ,Markets Amp Regulations ,Linical Evolution ,Financing Round ,Small Molecule Drugs ,Small Molecule ,